Altria shares hit after National Cancer Institute director named acting head of the FDA

Altria investors don't seem to like the prospects for the cigarette maker under the new acting FDA commissioner.

The company's stock fell to their lows of the day, trading around 0.3 percent lower, after National Cancer Institute Director Ned Sharpless was named interim head of the agency.

Sharpless' naming comes after Scott Gottlieb resigned last week from his post as FDA commissioner.

This is a developing story. Check back for updates.

Let's block ads! (Why?)

from Top News & Analysis https://ift.tt/2UFnNGs